3j2x › Citations

Structural analyses at pseudo atomic resolution of Chikungunya virus and antibodies show mechanisms of neutralization.

<div class='caption-title'>(A) Surface-shaded figure of ectodomain (left) and surface-shaded figure of nucleocapsid (right), colored according to the radial distance from the center of the virus. White triangles indicate one icosahedral asymmetric unit. (B) Cross-section of the virus showing density above 1.5 σ also colored according to the radial distance from the center of the virus. (C) Resolution of β-strands in the E1 domain III.</div>
<div class='caption-title'>(A) Diagrammatic organization of the E1 and E2 subunits according to T = 4 icosahedral symmetry. The white numbers show the sequence in which the four independent subunits were generated. The black capital letters indicate the sequence of generating seven of the icosahedral asymmetric units. Icosahedral symmetry elements are shown as filled triangles and ellipses. Quasi-symmetry elements are shown as red outlined triangles and ellipses. (B) Contacts between the E1 (blue) and E2 (green) molecules. (C) Contacts between NCPs. (B) and (C) show the number of contacts between the indicated molecules. The quasi T = 4 related positions #1, #2, #3 and #4 are indicated, prefixed by their icosahedral symmetry identification A, B, C and D. The center of the “i3” icosahedral spike is indicated by a filled red triangle and the center of the “q3” quasi-3-fold spike is indicated by an outlined red triangle.</div>
<div class='caption-title'>(A) Fit of the E1E2 heterodimer, (B) Fit of the capsid protein. The quasi equivalent subunit closest to the icosahedral 5-fold axis was chosen for display.</div>
Sun S, Xiang Y, Akahata W, Holdaway H, Pal P, Zhang X, Diamond MS, Nabel GJ, Rossmann MG
OpenAccess logo Elife 2 e00435 (2013)
Related entries: 3j2w, 3j2y, 3j2z, 3j30, 4gq9

Cited: 97 times
EuropePMC logo PMID: 23577234

Abstract

A 5.3 Å resolution, cryo-electron microscopy (cryoEM) map of Chikungunya virus-like particles (VLPs) has been interpreted using the previously published crystal structure of the Chikungunya E1-E2 glycoprotein heterodimer. The heterodimer structure was divided into domains to obtain a good fit to the cryoEM density. Differences in the T = 4 quasi-equivalent heterodimer components show their adaptation to different environments. The spikes on the icosahedral 3-fold axes and those in general positions are significantly different, possibly representing different phases during initial generation of fusogenic E1 trimers. CryoEM maps of neutralizing Fab fragments complexed with VLPs have been interpreted using the crystal structures of the Fab fragments and the VLP structure. Based on these analyses the CHK-152 antibody was shown to stabilize the viral surface, hindering the exposure of the fusion-loop, likely neutralizing infection by blocking fusion. The CHK-9, m10 and m242 antibodies surround the receptor-attachment site, probably inhibiting infection by blocking cell attachment. DOI:http://dx.doi.org/10.7554/eLife.00435.001.

Reviews citing this publication (21)

  1. Early Events in Chikungunya Virus Infection-From Virus Cell Binding to Membrane Fusion. van Duijl-Richter MK, Hoornweg TE, Rodenhuis-Zybert IA, Smit JM. Viruses 7 3647-3674 (2015)
  2. Common Features of Enveloped Viruses and Implications for Immunogen Design for Next-Generation Vaccines. Rey FA, Lok SM. Cell 172 1319-1334 (2018)
  3. Therapeutics and vaccines against chikungunya virus. Ahola T, Couderc T, Ng LF, Hallengärd D, Powers A, Lecuit M, Esteban M, Merits A, Roques P, Roques P, Liljeström P. Vector Borne Zoonotic Dis. 15 250-257 (2015)
  4. Alphavirus structure: activation for entry at the target cell surface. Vaney MC, Duquerroy S, Rey FA. Curr Opin Virol 3 151-158 (2013)
  5. Enveloped virus-like particles as vaccines against pathogenic arboviruses. Pijlman GP. Biotechnol J 10 659-670 (2015)
  6. Cryo-EM Studies of Virus-Antibody Immune Complexes. Li N, Li Z, Fu Y, Cao S. Virol Sin 35 1-13 (2020)
  7. Revisiting an old friend: new findings in alphavirus structure and assembly. Button JM, Qazi SA, Wang JC, Mukhopadhyay S. Curr Opin Virol 45 25-33 (2020)
  8. Requirement of Fc-Fc Gamma Receptor Interaction for Antibody-Based Protection against Emerging Virus Infections. Keeler SP, Fox JM. Viruses 13 1037 (2021)
  9. The Alphavirus Exit Pathway: What We Know and What We Wish We Knew. Brown RS, Wan JJ, Kielian M. Viruses 10 (2018)
  10. Antibody-based therapeutic interventions: possible strategy to counter chikungunya viral infection. Kumar R, Shrivastava T, Samal S, Ahmed S, Parray HA. Appl Microbiol Biotechnol 104 3209-3228 (2020)
  11. Inhibitory Antibodies Targeting Emerging Viruses: Advancements and Mechanisms. Jin J, Simmons G. Clin. Vaccine Immunol. 23 535-539 (2016)
  12. Alphavirus Virulence Determinants. Rangel MV, Stapleford KA. Pathogens 10 981 (2021)
  13. Beyond Fever and Pain: Diagnostic Methods for Chikungunya Virus. Natrajan MS, Rojas A, Waggoner JJ. J. Clin. Microbiol. 57 (2019)
  14. Dissecting Virus Infectious Cycles by Cryo-Electron Microscopy. Lee KK, Gui L. PLoS Pathog. 12 e1005625 (2016)
  15. A molecular understanding of alphavirus entry and antibody protection. Kim AS, Diamond MS. Nat Rev Microbiol (2022)
  16. Antiviral Functions of Monoclonal Antibodies against Chikungunya Virus. Jin J, Simmons G. Viruses 11 (2019)
  17. Chikungunya Vaccine Candidates: Current Landscape and Future Prospects. Schmidt C, Schnierle BS. Drug Des Devel Ther 16 3663-3673 (2022)
  18. Chikungunya and Zika Viruses: Co-Circulation and the Interplay between Viral Proteins and Host Factors. Wichit S, Gumpangseth N, Hamel R, Yainoy S, Arikit S, Punsawad C, Missé D. Pathogens 10 448 (2021)
  19. Insights into Antibody-Mediated Alphavirus Immunity and Vaccine Development Landscape. Torres-Ruesta A, Chee RS, Ng LFP. Microorganisms 9 899 (2021)
  20. Recent advances in therapeutic applications of neutralizing antibodies for virus infections: an overview. Ali MG, Zhang Z, Gao Q, Pan M, Rowan EG, Zhang J. Immunol Res 68 325-339 (2020)
  21. The Structural Biology of Eastern Equine Encephalitis Virus, an Emerging Viral Threat. Hasan SS, Dey D, Singh S, Martin M. Pathogens 10 973 (2021)

Articles citing this publication (76)

  1. Development of a highly protective combination monoclonal antibody therapy against Chikungunya virus. Pal P, Dowd KA, Brien JD, Edeling MA, Gorlatov S, Johnson S, Lee I, Akahata W, Nabel GJ, Richter MK, Smit JM, Fremont DH, Pierson TC, Heise MT, Diamond MS. PLoS Pathog. 9 e1003312 (2013)
  2. A neutralizing monoclonal antibody targeting the acid-sensitive region in chikungunya virus E2 protects from disease. Selvarajah S, Sexton NR, Kahle KM, Fong RH, Mattia KA, Gardner J, Lu K, Liss NM, Salvador B, Tucker DF, Barnes T, Mabila M, Zhou X, Rossini G, Rucker JB, Sanders DA, Suhrbier A, Sambri V, Michault A, Muench MO, Doranz BJ, Simmons G. PLoS Negl Trop Dis 7 e2423 (2013)
  3. Isolation and Characterization of Broad and Ultrapotent Human Monoclonal Antibodies with Therapeutic Activity against Chikungunya Virus. Smith SA, Silva LA, Fox JM, Flyak AI, Kose N, Sapparapu G, Khomandiak S, Ashbrook AW, Kahle KM, Fong RH, Swayne S, Doranz BJ, McGee CE, Heise MT, Pal P, Brien JD, Austin SK, Diamond MS, Dermody TS, Crowe JE. Cell Host Microbe 18 86-95 (2015)
  4. Broadly Neutralizing Alphavirus Antibodies Bind an Epitope on E2 and Inhibit Entry and Egress. Fox JM, Long F, Edeling MA, Lin H, van Duijl-Richter MKS, Fong RH, Kahle KM, Smit JM, Jin J, Simmons G, Doranz BJ, Crowe JE, Fremont DH, Rossmann MG, Diamond MS. Cell 163 1095-1107 (2015)
  5. A single-amino-acid polymorphism in Chikungunya virus E2 glycoprotein influences glycosaminoglycan utilization. Silva LA, Khomandiak S, Ashbrook AW, Weller R, Heise MT, Morrison TE, Dermody TS. J. Virol. 88 2385-2397 (2014)
  6. Optimal therapeutic activity of monoclonal antibodies against chikungunya virus requires Fc-FcγR interaction on monocytes. Fox JM, Roy V, Gunn BM, Huang L, Edeling MA, Mack M, Fremont DH, Doranz BJ, Johnson S, Alter G, Diamond MS. Sci Immunol 4 eaav5062 (2019)
  7. Exposure of epitope residues on the outer face of the chikungunya virus envelope trimer determines antibody neutralizing efficacy. Fong RH, Banik SS, Mattia K, Barnes T, Tucker D, Liss N, Lu K, Selvarajah S, Srinivasan S, Mabila M, Miller A, Muench MO, Michault A, Rucker JB, Paes C, Simmons G, Kahle KM, Doranz BJ. J. Virol. 88 14364-14379 (2014)
  8. A chikungunya fever vaccine utilizing an insect-specific virus platform. Erasmus JH, Auguste AJ, Kaelber JT, Luo H, Rossi SL, Fenton K, Leal G, Kim DY, Chiu W, Wang T, Frolov I, Nasar F, Weaver SC. Nat. Med. 23 192-199 (2017)
  9. Chikungunya viruses that escape monoclonal antibody therapy are clinically attenuated, stable, and not purified in mosquitoes. Pal P, Fox JM, Hawman DW, Huang YJ, Messaoudi I, Kreklywich C, Denton M, Legasse AW, Smith PP, Johnson S, Axthelm MK, Vanlandingham DL, Streblow DN, Higgs S, Morrison TE, Diamond MS. J. Virol. 88 8213-8226 (2014)
  10. Rapid and Long-Term Immunity Elicited by DNA-Encoded Antibody Prophylaxis and DNA Vaccination Against Chikungunya Virus. Muthumani K, Block P, Flingai S, Muruganantham N, Chaaithanya IK, Tingey C, Wise M, Reuschel EL, Chung C, Muthumani A, Sarangan G, Srikanth P, Khan AS, Vijayachari P, Sardesai NY, Kim JJ, Ugen KE, Weiner DB. J. Infect. Dis. 214 369-378 (2016)
  11. Locking and blocking the viral landscape of an alphavirus with neutralizing antibodies. Porta J, Jose J, Roehrig JT, Blair CD, Kuhn RJ, Rossmann MG. J. Virol. 88 9616-9623 (2014)
  12. Neutralizing Monoclonal Antibodies Block Chikungunya Virus Entry and Release by Targeting an Epitope Critical to Viral Pathogenesis. Jin J, Liss NM, Chen DH, Liao M, Fox JM, Shimak RM, Fong RH, Chafets D, Bakkour S, Keating S, Fomin ME, Muench MO, Sherman MB, Doranz BJ, Diamond MS, Simmons G. Cell Rep 13 2553-2564 (2015)
  13. Pathogenic Chikungunya Virus Evades B Cell Responses to Establish Persistence. Hawman DW, Fox JM, Ashbrook AW, May NA, Schroeder KMS, Torres RM, Crowe JE, Dermody TS, Diamond MS, Morrison TE. Cell Rep 16 1326-1338 (2016)
  14. A Virus-Like Particle Vaccine Elicits Broad Neutralizing Antibody Responses in Humans to All Chikungunya Virus Genotypes. Goo L, Dowd KA, Lin TY, Mascola JR, Graham BS, Ledgerwood JE, Pierson TC. J. Infect. Dis. 214 1487-1491 (2016)
  15. Cryo-EM structures elucidate neutralizing mechanisms of anti-chikungunya human monoclonal antibodies with therapeutic activity. Long F, Fong RH, Austin SK, Chen Z, Klose T, Fokine A, Liu Y, Porta J, Sapparapu G, Akahata W, Doranz BJ, Crowe JE, Diamond MS, Rossmann MG. Proc. Natl. Acad. Sci. U.S.A. 112 13898-13903 (2015)
  16. Enhanced production of Chikungunya virus-like particles using a high-pH adapted spodoptera frugiperda insect cell line. Wagner JM, Pajerowski JD, Daniels CL, McHugh PM, Flynn JA, Balliet JW, Casimiro DR, Subramanian S. PLoS ONE 9 e94401 (2014)
  17. Self-Assembly of an Alphavirus Core-like Particle Is Distinguished by Strong Intersubunit Association Energy and Structural Defects. Wang JC, Chen C, Rayaprolu V, Mukhopadhyay S, Zlotnick A. ACS Nano 9 8898-8906 (2015)
  18. Structural basis of Chikungunya virus inhibition by monoclonal antibodies. Zhou QF, Fox JM, Earnest JT, Ng TS, Kim AS, Fibriansah G, Kostyuchenko VA, Shi J, Shu B, Diamond MS, Lok SM. Proc Natl Acad Sci U S A 117 27637-27645 (2020)
  19. Characterisation of mouse monoclonal antibodies targeting linear epitopes on Chikungunya virus E2 glycoprotein. Chua CL, Chan YF, Sam IC. J. Virol. Methods 195 126-133 (2014)
  20. Mxra8 is a receptor for multiple arthritogenic alphaviruses. Zhang R, Kim AS, Fox JM, Nair S, Basore K, Klimstra WB, Rimkunas R, Fong RH, Lin H, Poddar S, Crowe JE, Doranz BJ, Fremont DH, Diamond MS. Nature 557 570-574 (2018)
  21. Cryo-EM Structure of Chikungunya Virus in Complex with the Mxra8 Receptor. Basore K, Kim AS, Nelson CA, Zhang R, Smith BK, Uranga C, Vang L, Cheng M, Gross ML, Smith J, Diamond MS, Fremont DH. Cell 177 1725-1737.e16 (2019)
  22. Residue-level resolution of alphavirus envelope protein interactions in pH-dependent fusion. Zeng X, Mukhopadhyay S, Brooks CL. Proc. Natl. Acad. Sci. U.S.A. 112 2034-2039 (2015)
  23. Single-residue posttranslational modification sites at the N-terminus, C-terminus or in-between: To be or not to be exposed for enzyme access. Sirota FL, Maurer-Stroh S, Eisenhaber B, Eisenhaber F. Proteomics 15 2525-2546 (2015)
  24. Cryo-EM structure of the mature and infective Mayaro virus at 4.4 Å resolution reveals features of arthritogenic alphaviruses. Ribeiro-Filho HV, Coimbra LD, Cassago A, Rocha RPF, Guerra JVDS, de Felicio R, Carnieli CM, Leme L, Padilha AC, Paes Leme AF, Trivella DBB, Portugal RV, Lopes-de-Oliveira PS, Marques RE. Nat Commun 12 3038 (2021)
  25. Structural Studies of Chikungunya Virus-Like Particles Complexed with Human Antibodies: Neutralization and Cell-to-Cell Transmission. Porta J, Mangala Prasad V, Wang CI, Akahata W, Ng LF, Rossmann MG. J. Virol. 90 1169-1177 (2016)
  26. An Alphavirus E2 Membrane-Proximal Domain Promotes Envelope Protein Lateral Interactions and Virus Budding. Byrd EA, Kielian M. MBio 8 (2017)
  27. Acidic pH-Induced Conformational Changes in Chikungunya Virus Fusion Protein E1: a Spring-Twisted Region in the Domain I-III Linker Acts as a Hinge Point for Swiveling Motion of Domains. Sahoo B, Gudigamolla NK, Chowdary TK. J Virol 94 e01561-20 (2020)
  28. Structural studies of Chikungunya virus maturation. Yap ML, Klose T, Urakami A, Hasan SS, Akahata W, Rossmann MG. Proc. Natl. Acad. Sci. U.S.A. 114 13703-13707 (2017)
  29. Anti-Chikungunya Virus Monoclonal Antibody That Inhibits Viral Fusion and Release. Tumkosit U, Siripanyaphinyo U, Takeda N, Tsuji M, Maeda Y, Ruchusatsawat K, Shioda T, Mizushima H, Chetanachan P, Wongjaroen P, Matsuura Y, Tatsumi M, Tanaka A. J Virol 94 e00252-20 (2020)
  30. Chikungunya E2 Protein Produced in E. coli and HEK293-T Cells-Comparison of Their Performances in ELISA. Bagno FF, Godói LC, Figueiredo MM, Sérgio SAR, Moraes TFS, Salazar NC, Kim YC, Reyes-Sandoval A, da Fonseca FG. Viruses 12 E939 (2020)
  31. Chikungunya virus assembly and budding visualized in situ using cryogenic electron tomography. Chmielewski D, Schmid MF, Simmons G, Jin J, Chiu W. Nat Microbiol 7 1270-1279 (2022)
  32. Cryo-EM structure of eastern equine encephalitis virus in complex with heparan sulfate analogues. Chen CL, Hasan SS, Klose T, Sun Y, Buda G, Sun C, Klimstra WB, Rossmann MG. Proc Natl Acad Sci U S A 117 8890-8899 (2020)
  33. Differing epidemiological dynamics of Chikungunya virus in the Americas during the 2014-2015 epidemic. Tan Y, Pickett BE, Shrivastava S, Gresh L, Balmaseda A, Amedeo P, Hu L, Puri V, Fedorova NB, Halpin RA, LaPointe MP, Cone MR, Heberlein-Larson L, Kramer LD, Ciota AT, Gordon A, Shabman RS, Das SR, Harris E. PLoS Negl Trop Dis 12 e0006670 (2018)
  34. Neutralizing Antibodies Inhibit Chikungunya Virus Budding at the Plasma Membrane. Jin J, Galaz-Montoya JG, Sherman MB, Sun SY, Goldsmith CS, O'Toole ET, Ackerman L, Carlson LA, Weaver SC, Chiu W, Simmons G. Cell Host Microbe 24 417-428.e5 (2018)
  35. The vaccinia virus based Sementis Copenhagen Vector vaccine against Zika and chikungunya is immunogenic in non-human primates. Prow NA, Liu L, McCarthy MK, Walters K, Kalkeri R, Geiger J, Koide F, Cooper TH, Eldi P, Nakayama E, Diener KR, Howley PM, Hayball JD, Morrison TE, Suhrbier A. NPJ Vaccines 5 44 (2020)
  36. Understanding the interactability of chikungunya virus proteins via molecular recognition feature analysis. Singh A, Kumar A, Uversky VN, Giri R. RSC Adv 8 27293-27303 (2018)
  37. Assembly, maturation and three-dimensional helical structure of the teratogenic rubella virus. Mangala Prasad V, Klose T, Rossmann MG. PLoS Pathog. 13 e1006377 (2017)
  38. Assessment of Immunogenicity and Neutralisation Efficacy of Viral-Vectored Vaccines Against Chikungunya Virus. López-Camacho C, Kim YC, Blight J, Lazaro Moreli M, Montoya-Diaz E, Huiskonen JT, Kümmerer BM, Reyes-Sandoval A. Viruses 11 (2019)
  39. Cell-Based Platform for Antigen Testing and Its Application for SARS-CoV-2 Infection. Ssemadaali MA, Newmyer S, Radhakrishnan H, Arredondo J, Javitz HS, Dandekar S, Bhatnagar P. Microbiol Spectr 10 e0073122 (2022)
  40. Chikungunya virus cell-to-cell transmission is mediated by intercellular extensions in vitro and in vivo. Yin P, Davenport BJ, Wan JJ, Kim AS, Diamond MS, Ware BC, Tong K, Couderc T, Lecuit M, Lai JR, Morrison TE, Kielian M. Nat Microbiol 8 1653-1667 (2023)
  41. Global Outbreaks and Origins of a Chikungunya Virus Variant Carrying Mutations Which May Increase Fitness for Aedes aegypti: Revelations from the 2016 Mandera, Kenya Outbreak. Maljkovic Berry I, Eyase F, Pollett S, Konongoi SL, Joyce MG, Figueroa K, Ofula V, Koka H, Koskei E, Nyunja A, Mancuso JD, Jarman RG, Sang R. Am. J. Trop. Med. Hyg. 100 1249-1257 (2019)
  42. Highly potent multivalent VHH antibodies against Chikungunya isolated from an alpaca naïve phage display library. Li Q, Zhang F, Lu Y, Hu H, Wang J, Guo C, Deng Q, Liao C, Wu Q, Hu T, Chen Z, Lu J. J Nanobiotechnology 20 231 (2022)
  43. Implication for alphavirus host-cell entry and assembly indicated by a 3.5Å resolution cryo-EM structure. Chen L, Wang M, Zhu D, Sun Z, Ma J, Wang J, Kong L, Wang S, Liu Z, Wei L, He Y, Wang J, Zhang X. Nat Commun 9 5326 (2018)
  44. Peptidomimetic Oligomers Targeting Membrane Phosphatidylserine Exhibit Broad Antiviral Activity. Tate PM, Mastrodomenico V, Cunha C, McClure J, Barron AE, Diamond G, Mounce BC, Kirshenbaum K. ACS Infect Dis 9 1508-1522 (2023)
  45. Structural basis for the shared neutralization mechanism of three classes of human papillomavirus type 58 antibodies with disparate modes of binding. He M, Chi X, Zha Z, Li Y, Chen J, Huang Y, Huang S, Yu M, Wang Z, Song S, Liu X, Wei S, Li Z, Li T, Wang Y, Yu H, Zhao Q, Zhang J, Zheng Q, Gu Y, Li S, Xia N. J Virol JVI.01587-20 (2021)
  46. Suramin Inhibits Chikungunya Virus Replication by Interacting with Virions and Blocking the Early Steps of Infection. Albulescu IC, White-Scholten L, Tas A, Hoornweg TE, Ferla S, Kovacikova K, Smit JM, Brancale A, Snijder EJ, van Hemert MJ. Viruses 12 (2020)
  47. Therapeutic alphavirus cross-reactive E1 human antibodies inhibit viral egress. Williamson LE, Reeder KM, Bailey K, Tran MH, Roy V, Fouch ME, Kose N, Trivette A, Nargi RS, Winkler ES, Kim AS, Gainza C, Rodriguez J, Armstrong E, Sutton RE, Reidy J, Carnahan RH, McDonald WH, Schoeder CT, Klimstra WB, Davidson E, Doranz BJ, Alter G, Meiler J, Schey KL, Julander JG, Diamond MS, Crowe JE. Cell 184 4430-4446.e22 (2021)
  48. A chikungunya virus-like particle vaccine induces broadly neutralizing and protective antibodies against alphaviruses in humans. Raju S, Adams LJ, Earnest JT, Warfield K, Vang L, Crowe JE, Fremont DH, Diamond MS. Sci Transl Med 15 eade8273 (2023)
  49. A cross-reactive antibody protects against Ross River virus musculoskeletal disease despite rapid neutralization escape in mice. Fox JM, Huang L, Tahan S, Powell LA, Crowe JE, Wang D, Diamond MS. PLoS Pathog 16 e1008743 (2020)
  50. Berberine Chloride is an Alphavirus Inhibitor That Targets Nucleocapsid Assembly. Wan JJ, Brown RS, Kielian M. mBio 11 (2020)
  51. Chikungunya Fever in Southern Thailand, 2018. Nanakorn N, Pengsakul T, Bunrod K, Thammapalo S, Prikchoo P, Vongpunsawad S, Poovorawan Y. Am J Trop Med Hyg 105 955-959 (2021)
  52. Chikungunya Virus' High Genomic Plasticity Enables Rapid Adaptation to Restrictive A549 Cells. De Caluwé L, Heyndrickx L, Coppens S, Vereecken K, Quiñones-Mateu ME, Merits A, Ariën KK, Bartholomeeusen K. Viruses 14 282 (2022)
  53. Chikungunya virus entry and infectivity is primarily facilitated through cell line dependent attachment factors in mammalian and mosquito cells. Reyes Ballista JM, Miazgowicz KL, Acciani MD, Jimenez AR, Belloli RS, Havranek KE, Brindley MA. Front Cell Dev Biol 11 1085913 (2023)
  54. Comprehensive Flow Cytometry Analysis of PEI-Based Transfections for Virus-Like Particle Production. Blackstock DJ, Goh A, Shetty S, Fabozzi G, Yang R, Ivleva VB, Schwartz R, Horwitz J. Research (Wash D C) 2020 1387402 (2020)
  55. Conformational changes in Chikungunya virus E2 protein upon heparan sulfate receptor binding explain mechanism of E2-E1 dissociation during viral entry. Sahoo B, Chowdary TK. Biosci. Rep. 39 (2019)
  56. Cooperative Chikungunya Virus Membrane Fusion and Its Substoichiometric Inhibition by CHK-152 Antibody. Blijleven JS, Bouma EM, van Duijl-Richter MKS, Smit JM, van Oijen AM. Viruses 14 270 (2022)
  57. Cryo-EM Structures of Eastern Equine Encephalitis Virus Reveal Mechanisms of Virus Disassembly and Antibody Neutralization. Hasan SS, Sun C, Kim AS, Watanabe Y, Chen CL, Klose T, Buda G, Crispin M, Diamond MS, Klimstra WB, Rossmann MG. Cell Rep 25 3136-3147.e5 (2018)
  58. Cryo-EM structure of severe fever with thrombocytopenia syndrome virus. Du S, Peng R, Xu W, Qu X, Wang Y, Wang J, Li L, Tian M, Guan Y, Wang J, Wang G, Li H, Deng L, Shi X, Ma Y, Liu F, Sun M, Wei Z, Jin N, Liu W, Qi J, Liu Q, Liao M, Li C. Nat Commun 14 6333 (2023)
  59. Cryo-EM structures of alphavirus conformational intermediates in low pH-triggered prefusion states. Chen CL, Klose T, Sun C, Kim AS, Buda G, Rossmann MG, Diamond MS, Klimstra WB, Kuhn RJ. Proc Natl Acad Sci U S A 119 e2114119119 (2022)
  60. Development of Viral-Vectored Vaccines and Virus Replicon Particle-Based Neutralisation Assay against Mayaro Virus. Kim YC, Lücke AC, López-Camacho C, Kümmerer BM, Reyes-Sandoval A. Int J Mol Sci 23 4105 (2022)
  61. Heterologous DNA Prime- Subunit Protein Boost with Chikungunya Virus E2 Induces Neutralizing Antibodies and Cellular-Mediated Immunity. Coirada FC, Fernandes ER, Mello LR, Schuch V, Soares Campos G, Braconi CT, Boscardin SB, Santoro Rosa D. Int J Mol Sci 24 10517 (2023)
  62. Human Antibodies Protect against Aerosolized Eastern Equine Encephalitis Virus Infection. Williamson LE, Gilliland T, Yadav PK, Binshtein E, Bombardi R, Kose N, Nargi RS, Sutton RE, Durie CL, Armstrong E, Carnahan RH, Walker LM, Kim AS, Fox JM, Diamond MS, Ohi MD, Klimstra WB, Crowe JE. Cell 183 1884-1900.e23 (2020)
  63. Human monoclonal antibodies against chikungunya virus target multiple distinct epitopes in the E1 and E2 glycoproteins. Quiroz JA, Malonis RJ, Thackray LB, Cohen CA, Pallesen J, Jangra RK, Brown RS, Hofmann D, Holtsberg FW, Shulenin S, Nyakatura EK, Durnell LA, Rayannavar V, Daily JP, Ward AB, Aman MJ, Dye JM, Chandran K, Diamond MS, Kielian M, Lai JR. PLoS Pathog. 15 e1008061 (2019)
  64. Immunoproteomic analysis of a Chikungunya poxvirus-based vaccine reveals high HLA class II immunoprevalence. Lorente E, Barriga A, Barnea E, Palomo C, García-Arriaza J, Mir C, Esteban M, Admon A, López D. PLoS Negl Trop Dis 13 e0007547 (2019)
  65. Isolation and characterization of high affinity and highly stable anti-Chikungunya virus antibodies using ALTHEA Gold Libraries™. Pedraza-Escalona M, Guzmán-Bringas O, Arrieta-Oliva HI, Gómez-Castellano K, Salinas-Trujano J, Torres-Flores J, Muñoz-Herrera JC, Camacho-Sandoval R, Contreras-Pineda P, Chacón-Salinas R, Pérez-Tapia SM, Almagro JC. BMC Infect Dis 21 1121 (2021)
  66. Molecular Docking Studies to Explore Potential Binding Pockets and Inhibitors for Chikungunya Virus Envelope Glycoproteins. Nguyen PTV, Yu H, Keller PA. Interdiscip Sci 10 515-524 (2018)
  67. Molecular organization and dynamics of the fusion protein Gc at the hantavirus surface. Bignon EA, Albornoz A, Guardado-Calvo P, Rey FA, Tischler ND. Elife 8 (2019)
  68. Mutation of N-glycosylation Sites in Salmonid Alphavirus (SAV) Envelope Proteins Attenuate the Virus in Cell Culture. Aksnes I, Markussen T, Braaen S, Rimstad E. Viruses 12 (2020)
  69. Prediction of MAYV peptide antigens for immunodiagnostic tests by immunoinformatics and molecular dynamics simulations. Rodrigues RL, Menezes GL, Saivish MV, Costa VGD, Pereira M, Moreli ML, Silva RAD. Sci Rep 9 13339 (2019)
  70. Removing the Polyanionic Cargo Requirement for Assembly of Alphavirus Core-Like Particles to Make an Empty Alphavirus Core. Button JM, Mukhopadhyay S. Viruses 12 (2020)
  71. Species-specific MARCO-alphavirus interactions dictate chikungunya virus viremia. Li FS, Carpentier KS, Hawman DW, Lucas CJ, Ander SE, Feldmann H, Morrison TE. Cell Rep 42 112418 (2023)
  72. Structural constraints link differences in neutralization potency of human anti-Eastern equine encephalitis virus monoclonal antibodies. Williamson LE, Bandyopadhyay A, Bailey K, Sirohi D, Klose T, Julander JG, Kuhn RJ, Crowe JE. Proc Natl Acad Sci U S A 120 e2213690120 (2023)
  73. Structures of enveloped virions determined by cryogenic electron microscopy and tomography. Stass R, Ng WM, Kim YC, Huiskonen JT. Adv Virus Res 105 35-71 (2019)
  74. The effect of amantadine on an ion channel protein from Chikungunya virus. Dey D, Siddiqui SI, Mamidi P, Ghosh S, Kumar CS, Chattopadhyay S, Ghosh S, Banerjee M. PLoS Negl Trop Dis 13 e0007548 (2019)
  75. The vaccinia virus based Sementis Copenhagen Vector vaccine against Zika and chikungunya is immunogenic in non-human primates. Prow NA, Liu L, McCarthy MK, Walters K, Kalkeri R, Geiger J, Koide F, Cooper TH, Eldi P, Nakayama E, Diener KR, Howley PM, Hayball JD, Morrison TE, Suhrbier A. NPJ Vaccines 5 44 (2020)
  76. Visualization of conformational changes and membrane remodeling leading to genome delivery by viral class-II fusion machinery. Mangala Prasad V, Blijleven JS, Smit JM, Lee KK. Nat Commun 13 4772 (2022)


Quick links